Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/IIa Safety and Efficacy of PM8002, a Bispecific Antibody Targeting PD-L1 and VEGF-A, as a Monotherapy in Patients With Advanced Solid Tumors

NCT05918445 is registered in ClinicalTrials.gov with Biotheus Inc. as lead sponsor.

NCT NCT05918445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05918445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/IIa Safety and Efficacy of PM8002, a Bispecific Antibody Targeting PD-L1 and VEGF-A, as a Monotherapy in Patients With Advanced Solid Tumors
Lead sponsor
Biotheus Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 9, 2021
Completion date
November 30, 2025
Enrollment
380 (estimated)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

malignant neoplasm